Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.88 USD
-0.21 (-4.13%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $4.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 1 - 20 ( 406 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Intranasal Epinephrine Approval Mitigates Regulatory Risk; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Anaphylm? Approaches FDA Submission; 2Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Another Anaphylm? Gating Item Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Anaphylm Commercial Leadership Incepted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
1Q24 Financials; Anaphylm NDA Filing Approaches; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant Notches First Full Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Equity Financing Complete; Competitor Resubmission; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Anaphylm Pivotal Trial Positive Data Across the Board; Raising PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Anaphylm Pivotal Trial Completion Nears; 2023 Financials; Raising PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q4/FY23: Pivotal PK Readout for Anaphylm in March, NDA Filing Before YE:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Aquestive Therapeutics Management Access Webinar Invite - Feb. 23 @ 11AM ET
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Anaphylm Phase 3 Trial Patient Dosing Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q3: Pivotal PK Study for Anaphylm Set to Initiate in Q4:23, Readout in Q1:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Top- and Bottom-Line 3Q23 Beat; Debt Favorably Refinanced; Raising PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Positive FDA Feedback Puts Anaphylm On-Track to Topline Readout in Q1:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A